Verrica (VRCA) Q2 2026 earnings review
Volume Surges, but Unit Economics Deteriorate
Verrica is executing well on physician adoption but struggling to monetize it. YCANTH dispensed applicator units surged 46% YoY to a record 19,626. However, US product revenue grew just 12% to $5.1 million. This severe gross-to-net margin pressure, combined with R&D expenses jumping 233% to fund the common warts Phase 3 trial, pushed the net loss to $13.2 million. With cash dwindling to $11.2 million, Verrica secured a $27.5 million credit facility from an entity controlled by its Chairman to extend its runway into 2028. The volume thesis is intact, but the cash burn and pricing power are major red flags.
🐂 Bull Case
Physician and patient demand is accelerating. Dispensed units reached a record 19,626, up 28% sequentially. The expanded sales force is successfully driving prescription volume.
The Phase 3 COVE-2 and COVE-3 trials for common warts are actively enrolling. With an addressable market of 22 million US patients (over 3x the molluscum market), mid-2027 data represents a critical, company-altering catalyst.
🐻 Bear Case
Volume growth is vastly outpacing revenue growth. Aggressive commercial co-pay programs (capping patient costs at $25) are destroying gross-to-net margins. Verrica is selling more product for fewer dollars per unit.
Cash dropped to a dangerously low $11.2 million. The company is now relying on a $27.5 million credit facility from its Chairman to survive, highlighting the lack of attractive external financing options.
⚖️ Verdict: 🔴
Bearish. While Verrica is proving dermatologists want YCANTH, the financial model is currently broken. Operating expenses are surging while revenue yields compress, forcing the company to rely on insider debt to fund its ambitious clinical pipeline.
Key Themes
The Gross-to-Net Contradiction
Management touted a 46% YoY increase in YCANTH dispensed units, framing it as a major commercial success. However, U.S. product revenue only grew 12% YoY. We calculate that the implied net revenue per dispensed unit has collapsed from roughly $337 in Q2 2025 to just $260 in Q2 2026. This contradicts the bullish commercial narrative and indicates that the $25 co-pay assistance program is severely cannibalizing realized pricing.
Insider Debt Lifeline Highlights Cash Crunch
Verrica burned through significant cash, ending Q2 with just $11.2 million (down from $30.1M six months ago). To avoid a liquidity crisis, they secured a $27.5 million credit facility from an entity controlled by Paul B. Manning, Verrica's Chairman and largest shareholder. While this non-dilutive capital officially extends the runway into 2028, turning to a board member for a bailout underscores the harsh macro financing environment for unprofitable biotech firms.
Sales Force Expansion Yielding Volume
The strategic decision to expand the sales force to approximately 50 representatives is working on the volume side. Dispensed units grew 28% sequentially from Q1 2026. SG&A rose $1.3 million YoY to support this commercial spend, but it is successfully establishing YCANTH as the standard of care for molluscum.
Common Warts Phase 3 Progress
The global Phase 3 program for common warts is advancing. The first patients in the U.S. and Japan were dosed in the COVE-3 trial this quarter. With partner Torii funding the first $40 million of this program, Verrica is efficiently advancing a label expansion that targets an estimated 22 million U.S. patients.
VP-315 Innovation: Abscopal Effects Validated
Management highlighted Phase 2 data presented at the Society for Investigative Dermatology (SID) for its oncolytic peptide, VP-315, in basal cell carcinoma. The data showed an ability to impact both treated lesions and evidence of a meaningful 'abscopal effect' in untreated lesions. This unique technological profile strengthens the asset's positioning as it heads toward Phase 3 readiness.
Surging R&D Expenses
Despite the Torii cost-sharing agreement, reported R&D expenses spiked dramatically to $6.0 million, up 233% from $1.8 million in Q2 2025. Management attributed this to costs associated with the Phase 3 common warts program. While Torii is funding the first $40 million, the timing of cash inflows versus GAAP expense recognition is creating near-term pressure on the P&L.
Other KPIs
Accelerating. Total expenses surged 69% YoY. Beyond the commercial and R&D ramp-up, the company recorded a $1.7 million legal settlement expense net of insurance recovery to resolve a 2022 class-action lawsuit. Clearing this legal overhang is positive, but it weighed heavily on the quarter's cash profile.
Decelerating severely YoY. In Q2 2025, this line item was $8.2 million due to a one-time $8.0 million milestone payment from Torii. The current quarter's $0.8 million consists of routine commercial supply for Torii's launch in Japan. Investors must strip out the 2025 milestone to see the true organic YoY comparisons.
Guidance
Accelerating. Previously guided to Q1 2027 during the prior quarter's call, the runway has been drastically extended. However, this assumes the full availability and drawdown of the new $27.5 million credit facility from the Chairman. It is a debt-fueled extension rather than one driven by operational cash flow.
Stable. The company remains on track to deliver critical data for COVE-2 and COVE-3 by mid-2027, maintaining the timeline for its most important pipeline catalyst.
Key Questions
Gross-to-Net Stabilization
Unit volume grew 46% YoY, but net product revenue grew only 12%, implying a severe drop in realized revenue per unit. At what point does the gross-to-net discount driven by the $25 co-pay program stabilize, and when will revenue growth more closely mirror volume growth?
Chairman Credit Facility Terms
Regarding the new $27.5 million credit facility from Paul Manning's entity: what are the specific interest rates, draw-down conditions, and potential equity conversion features associated with this debt?
Torii Funding Mechanics
R&D expenses jumped to $6.0 million this quarter for the Phase 3 common warts trial. Since Torii is funding the first $40 million of this program, can you explain the accounting lag between the recognized GAAP R&D expense and the actual receipt of Torii's cash on the balance sheet?